BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8049441)

  • 41. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
    Montuori N; Salzano S; Rossi G; Ragno P
    FEBS Lett; 2000 Jul; 476(3):166-70. PubMed ID: 10913606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
    Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
    Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade.
    Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
    Eur J Biochem; 2002 Aug; 269(16):3945-57. PubMed ID: 12180971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
    Pluskota E; Soloviev DA; Plow EF
    Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
    Okusa Y; Ichikura T; Mochizuki H; Shinomiya N
    Int J Oncol; 2000 Nov; 17(5):1001-5. PubMed ID: 11029504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87).
    Coleman JL; Gebbia JA; Benach JL
    J Immunol; 2001 Jan; 166(1):473-80. PubMed ID: 11123326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells.
    Shetty S; Idell S
    J Biol Chem; 2001 Jul; 276(27):24549-56. PubMed ID: 11342540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
    Biliran H; Sheng S
    Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
    Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
    EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
    Mazumdar A; Adam L; Boyd D; Kumar R
    Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.